Boston University's National Emerging Infectious Diseases Laboratories (NEIDL) has received final approval from the Boston Public Health Commission to conduct research at Biosafety Level 4 (BSL-4). After years of scrutiny by regulatory agencies and city, state, and federal officials, the $200 million laboratory will now be able to work with approved BSL-4 pathogens such as Ebola and Marburg. The seven-story, 192,000-sf facility is part of a national network of secure facilities that study emerging infectious diseases and develop diagnostic tests, treatments, and vaccines to promote public health. NEIDL was completed in fall of 2008 and received BSL-4 research approval from the Centers for Disease Control and Prevention in December of 2016.
